PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2021.102202136122-29Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor AgonistsHun Jee Choe, Young Min Chohttp://e-enm.org/upload/pdf/enm-2021-102.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.102, http://e-enm.org/upload/pdf/enm-2021-102.pdf
European Journal of Pharmacology10.1016/j.ejphar.2004.08.02320045011-3225-234Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonistsQing Dallas-Yang, Xiaolan Shen, Mathias Strowski, Edward Brady, Richard Saperstein, Raymond E. Gibson, Deborah Szalkowski, Sajjad A. Qureshi, Mari Rios Candelore, Judith E. Fenyk-Melody, Emma R. Parmee, Bei B. Zhang, Guoqiang Jianghttps://api.elsevier.com/content/article/PII:S0014299904009355?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0014299904009355?httpAccept=text/plain
Diabetes, Obesity and Metabolism10.1111/dom.146402022245788-805Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaalhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640
Handbook of Incretin-based Therapies in Type 2 Diabetes10.1007/978-3-319-08982-9_3201631-43Glucagon-like peptide-1 receptor agonistsBaptist Gallwitzhttp://link.springer.com/content/pdf/10.1007/978-3-319-08982-9_3
Diabetes Care10.2337/dc11-s231201134Supplement_2S279-S284Long-Acting Glucagon-Like Peptide 1 Receptor AgonistsAlan J. Garberhttps://diabetesjournals.org/care/article-pdf/34/Supplement_2/S279/609257/s279.pdf, https://diabetesjournals.org/care/article-pdf/34/Supplement_2/S279/609257/s279.pdf
Journal of Cardiovascular Pharmacology and Therapeutics10.1177/10742484221146371202227107424842211463Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current EvidenceEmir M. Muzurović, Špela Volčanšek, Karin Zibar Tomšić, Andrej Janež, Dimitri P. Mikhailidis, Manfredi Rizzo, Christos S. Mantzoroshttp://journals.sagepub.com/doi/pdf/10.1177/10742484221146371, http://journals.sagepub.com/doi/full-xml/10.1177/10742484221146371, http://journals.sagepub.com/doi/pdf/10.1177/10742484221146371
Pancreatology10.1016/j.pan.2019.05.115201919S45-S46Risk of acute pancreatitis after glucagon-like peptide-1 receptor agonistsAdriana Gherbonhttps://api.elsevier.com/content/article/PII:S1424390319302182?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1424390319302182?httpAccept=text/plain
Diabetes Spectrum10.2337/ds16-00262017303202-210Glucagon-Like Peptide 1 Receptor Agonists for Type 2 DiabetesDeborah Hinnenhttps://diabetesjournals.org/spectrum/article-pdf/30/3/202/505130/202.pdf, https://diabetesjournals.org/spectrum/article-pdf/30/3/202/505130/202.pdf
Cardiovascular Research10.1093/cvr/cvac1122022Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonistsSten Madsbad, Jens J Holsthttps://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvac112/45281544/cvac112.pdf, https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvac112/45281544/cvac112.pdf
Progress in Medicinal Chemistry10.1016/b978-0-444-62652-3.00002-8201345-96Medicinal Chemistry of Glucagon-Like Peptide Receptor AgonistsLyn H. Jones, David A. Pricehttps://api.elsevier.com/content/article/PII:B9780444626523000028?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780444626523000028?httpAccept=text/plain